Virios Therapeutics (VIRI) Competitors $4.80 -0.03 (-0.62%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. ARCT, MBX, CMPX, TERN, HUMA, PRTA, HRTX, AMRN, PRME, and SNDLShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Arcturus Therapeutics (ARCT), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Arcturus Therapeutics MBX Biosciences Compass Therapeutics Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Arcturus Therapeutics (NASDAQ:ARCT) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Which has preferable valuation & earnings, ARCT or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M2.43-$80.94M-$2.53-5.39Virios TherapeuticsN/AN/A-$5.30M-$0.27-17.78 Which has more risk and volatility, ARCT or VIRI? Arcturus Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Is ARCT or VIRI more profitable? Virios Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-47.47% -27.41% -19.01% Virios Therapeutics N/A -130.33%-115.00% Do analysts rate ARCT or VIRI? Arcturus Therapeutics presently has a consensus target price of $54.00, suggesting a potential upside of 296.04%. Virios Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 4.17%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to ARCT or VIRI? In the previous week, Arcturus Therapeutics had 10 more articles in the media than Virios Therapeutics. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 0 mentions for Virios Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.00 beat Virios Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Arcturus Therapeutics Positive Virios Therapeutics Neutral Do institutionals & insiders believe in ARCT or VIRI? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryArcturus Therapeutics beats Virios Therapeutics on 13 of the 16 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.44M$790.73M$5.54B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio-17.781.3527.4320.23Price / SalesN/A226.97422.11118.64Price / CashN/A23.4436.8958.07Price / Book24.006.298.045.67Net Income-$5.30M-$27.73M$3.18B$249.13M7 Day Performance1.91%1.82%2.89%3.28%1 Month Performance-10.11%9.90%3.70%5.56%1 Year Performance1,977.02%10.79%36.15%21.12% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$4.80-0.6%$5.00+4.2%+1,899.2%$92.44MN/A-17.785ARCTArcturus Therapeutics3.7849 of 5 stars$13.01-2.4%$53.50+311.2%-37.8%$361.52M$152.31M-5.14180News CoverageAnalyst ForecastMBXMBX Biosciences3.1241 of 5 stars$11.41+6.1%$37.50+228.7%N/A$359.31MN/A0.0036CMPXCompass Therapeutics3.3893 of 5 stars$2.60+1.6%$13.13+404.8%+238.4%$354M$850K-6.3420Analyst UpgradeTERNTerns Pharmaceuticals3.9532 of 5 stars$3.73-2.6%$15.63+318.9%-38.3%$334.50MN/A-3.4240HUMAHumacyte2.3547 of 5 stars$2.09-1.4%$11.71+460.5%-60.1%$328.85M$1.57M-3.03150PRTAProthena3.1601 of 5 stars$6.07-0.2%$31.50+418.9%-67.8%$327.27M$135.16M-2.92130HRTXHeron Therapeutics4.0557 of 5 stars$2.07-3.3%$5.00+141.5%-21.8%$326.49M$144.29M-34.50300News CoverageAMRNAmarin0.9112 of 5 stars$16.22+3.2%$12.00-26.0%+18.0%$325.31M$228.61M-4.46360High Trading VolumePRMEPrime Medicine3.7591 of 5 stars$2.47+2.1%$10.08+308.2%-40.8%$324.30M$3.85M-1.20234Gap UpHigh Trading VolumeSNDLSNDL3.6718 of 5 stars$1.21-1.6%$3.63+199.6%-34.9%$323.21M$671.81M-4.172,516News Coverage Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives MBX Biosciences Alternatives Compass Therapeutics Alternatives Terns Pharmaceuticals Alternatives Humacyte Alternatives Prothena Alternatives Heron Therapeutics Alternatives Amarin Alternatives Prime Medicine Alternatives SNDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts